Influenza Tests Devices Market is predicted to reach USD 0.70 billion at a CAGR of 7.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Influenza Tests Devices Market”.

Market Research Future (MRFR) has published a cooked research report on the “Influenza Tests Devices Market” that contains information from 2018 to 2032. The Influenza Tests Devices Market is estimated to register a CAGR of 7.00% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Influenza test devices Market— Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc.

Influenza Tests Devices Market Highlights

The global Influenza Tests Devices Market is accounted to register a CAGR of 7.00% during the forecast period and is estimated to reach USD 0.70 billion by 2032.

The demand for influenza test devices is expected to rise due to the increasing incidence of chronic diseases, a growing elderly population, government initiatives to monitor influenza, and the development of advanced influenza diagnostic tests.

Explore In-depth Details: Influenza Tests Devices Market Size Report

Segment Analysis

The global Influenza Tests Devices Market has been segmented based on the Tests.

Based on the Tests, the market is segmented into Influenza Multiplex NAATs, Influenza Antigen Tests, and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs). The Influenza Multiplex NAATs segment was attributed to holding the largest market share in 2022.  

Nucleic Acid Amplification Tests (NAATs) have received authorization for application in various settings, including laboratory facilities with trained personnel (laboratory-based) and point-of-care (POC) settings. Certain NAATs are designed for self-administration at home or other non-healthcare locations. Rapid NAATs conducted at or near the specimen collection site can yield results within minutes, while the time required for laboratory-based NAATs varies from less than an hour to over a day.

Regional Analysis

The global Influenza Tests Devices Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Influenza Tests Devices Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Influenza Tests Devices Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Influenza test devices Market comprises of Middle East, Africa, and Latin America.

The largest market share for the Influenza Tests Devices Market was maintained by the North American regional sector. The expansion in this sector is a result of heightened government surveillance and the involvement of major industry players. As of August 2020, the U.S. FDA had granted approval for 13 rapid influenza diagnostic tests (limited to antigen detection, excluding test kits) and 11 multiplex assays capable of detecting influenza viruses and COVID-19. Additionally, U.S. healthcare authorities issued testing guidance for clinicians regarding both COVID-19 and the flu virus. Key manufacturers in this field include Becton Dickinson & Co., Quidel Corp., and Roche Molecular Systems, Inc.

Moreover, the Europe market has been persistently growing over the forecast period. The increasing elderly population is projected to play a pivotal role in driving market growth. As of 2022, over one-fifth (21.1%) of the EU population was aged 65 and above. The median age of the EU's population is on the rise, reaching 44.4 years as of January 1, 2022, signifying that half of the EU's population surpassed this age. The elderly demographic is susceptible to various diseases, including influenza.

In Asia Pacific, the primary factors driving growth in the region include a sizable patient population, strengthened government collaborations, and improvements in healthcare infrastructure. Various Southeast Asia and Pacific regions have partnered with international organizations like WHO to address challenges, with common obstacles including a scarcity of flu-positive samples, limited representation for specimen collection, and difficulties in shipping samples. In October 2020, Fujifilm Toyama Chemical Co., Ltd. officially announced a collaboration with Chinese firm Carelink Pharmaceuticals to introduce Avigan, an anti-influenza drug tablet, in China. The memorandum grants Carelink Pharmaceuticals exclusive authorization to file a request for the import clearance of the medicine. Fujifilm also expressed its intention to collaborate with Carelink to develop an injectable version of the medication

Furthermore, the rest of the world's Influenza Tests Devices Market is divided into the Middle East, Africa, and Latin America. The regional market is expected to experience growth, primarily propelled by the increasing prevalence of influenza. In 2020, Latin America and the Caribbean reported nearly a thousand registered cases of influenza, reflecting a significant decrease of approximately 74% compared to 2016, when the region documented over 35 thousand influenza infections. Sub-Saharan Africa recorded an estimated 7,000 influenza-related deaths in 2015, making it the most prevalent and lethal global disease. The mortality rate of influenza in sub-Saharan Africa disproportionately affects children under the age of five and individuals over 75.

Key Findings of the Study

• The global Influenza Tests Devices Market is expected to reach USD 0.70 billion by 2032, at a CAGR of 7.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the growing geriatric population, rising health awareness among the people, and rising healthcare expenditure.


• Based on Tests, the Influenza Multiplex NAATs segment was attributed to holding the largest market in 2022, with an approximate market share of 55–60%.


• Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc.